Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo.

BACKGROUND: Achieving a functional or sterilizing cure for HIV will require identification of therapeutic interventions that reduce HIV reservoir size in infected individuals. Proteasome inhibitors, such as ixazomib, impact multiple aspects of HIV biology including latency, transcription initiation,...

Descripción completa

Detalles Bibliográficos
Autores principales: Cummins, Nathan W, Baker, Jason, Chakraborty, Rana, Dean, Patrick G, Garcia-Rivera, Enrique, Krogman, Ashton, Kumar, Shaji, Kuzmichev, Yury V, Laird, Gregory M, Landay, Alan, Lichterfeld, Mathias, Mahmood, Maryam, Martinson, Jeffrey, Maynes, Mark, Natesampillai, Sekar, Rajkumar, Vincent, Rassadkina, Yelizaveta, Ritter, Kristen D., Rivera, Christina G, Rizza, Stacey A, Subramanian, Krupa, Tande, Aaron J, Wonderlich, Elizabeth R, Whitaker, Jennifer A, Zeuli, John, Badley, Andrew D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639424/
https://www.ncbi.nlm.nih.gov/pubmed/34901797
http://dx.doi.org/10.1016/j.eclinm.2021.101225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639424/
https://www.ncbi.nlm.nih.gov/pubmed/34901797
http://dx.doi.org/10.1016/j.eclinm.2021.101225

Ejemplares similares